Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Veradermics, Inc

NYSE: MANE · Life Sciences · 6 alerts · CIK 1827635

Share price
$128.05Close, Nov 16
Market cap
$5.4B
Shares outstanding
42.2MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Veradermics, Inc filings on SEC EDGAR ↗

9:04 AM ET 8-K
Clinical Trial Data

Veradermics Clinical Trial Data

Veradermics announced positive 12-month topline results from Part B of its Phase 2/3 Study '302' evaluating VDPHL01 for male pattern hair loss. The data showed significant increases in non-vellus hair counts and high rates of patient-reported visible improvement with no new safety signals. These results support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss in nearly 30 years.

Term
12 months
9:06 AM ET 8-K
Clinical Trial Data

Veradermics Clinical Trial Data

Veradermics announced positive topline results from its Phase 3 '304' clinical trial of VDPHL01 for male pattern hair loss, meeting all primary and secondary endpoints with high statistical significance. The study demonstrated robust increases in hair count and rapid onset of activity as early as Month 2, with a favorable safety profile and no treatment-related serious adverse events. These results, combined with prior Phase 2/3 data, support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss.

Term
6 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.